A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

Cancer

Volumn 119, Issue 15, 2013, Pages 2692-2700

  Kim, Edward J ^a   Ben Josef, Edgar ^b   Herman, Joseph M ^c   Bekaii Saab, Tanios ^d   Dawson, Laura A ^e   Griffith, Kent A ^f   Francis, Isaac R ^a   Greenson, Joel K ^a   Simeone, Diane M ^b   Lawrence, Theodore S ^b   Laheru, Daniel ^c   Wolfgang, Christopher L ^c   Williams, Terence ^d   Bloomston, Mark ^d   Moore, Malcolm J ^g   Wei, Alice ^g   Zalupski, Mark M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

gemcitabine; neoadjuvant; oxaliplatin; pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CREATINE KINASE; CREATININE; GEMCITABINE; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BLEEDING; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOPULMONARY INSUFFICIENCY; CAUSE OF DEATH; CHOLANGITIS; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEHYDRATION; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; ENTERITIS; FAINTNESS; FATIGUE; FEMALE; HEALTH STATUS; HEMATOLOGIC DISEASE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; INFECTION; INOPERABLE CANCER; INTESTINE PERFORATION; LAPAROTOMY; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OPERATION DURATION; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS FUNCTION; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PREOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RASH; SAFETY; SIDE EFFECT; SUDDEN DEATH; SURGICAL MORTALITY; SURVIVAL TIME; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

GEMCITABINE; NEOADJUVANT; OXALIPLATIN; PANCREATIC CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS;

EID: 84880573171     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28117     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304: 1073-1081.
3. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-277.
4. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008; 299: 1019-1026.
5. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S,. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997; 21: 195-200.
6. Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg. 1994; 167: 104-111; discussion 111-103.
7. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001; 5: 121-130.
8. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C,. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011; 15: 2059-2069.
9. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3502.
10. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487-3495.
11. Desai SP, Ben-Josef E, Normolle DP, et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol. 2007; 25: 4587-4592.
12. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS,. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro- 2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996; 34: 867-872.
13. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001; 19: 4202-4208.
14. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23: 3509-3516.
15. Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS,. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol. 2008; 1: 36-43.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
17. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127: 1335-1339.
18. Muler JH, McGinn CJ, Normolle D, et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol. 2004; 22: 238-243.
19. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26: 942-947.
20. Talamonti MS, Small W, Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006; 13: 150-158.
21. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA,. Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34: 107-116.
22. Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011; 29: 4105-4112.
23. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206: 833-846; discussion 846-838.
24. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011; 104: 155-161.
25. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg. Oncol. 2011; 18: 619-627.
26. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC,. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009; 16: 1727-1733.
27. Donahue TR, Isacoff WH, Hines OJ, et al. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg. 2011; 146: 836-843.
28. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012; 118: 5749-5756.
29. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
30. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P,. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007; 25: 2607-2615.
31. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ,. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011; 150: 466-473.
32. Ben-Josef E, Schipper M, Francis IR, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012; 84: 1166-1171.
33. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006; 13: 1035-1046.